Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-06-22
2004-08-24
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024100, C536S024500, C435S006120, C435S375000, C514S002600
Reexamination Certificate
active
06780850
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compositions comprising polynucleotides that specifically bind to a target protein and to methods for extending the half-life of such polynucleotides in vivo. The compositions are complexes, either covalent or non-covalent, of the polynucleotide and a protein (other than the target protein). The complexes typically include the 5′ or 3′ end or both of the polynucleotide.
BACKGROUND OF THE INVENTION
Aptamers are nucleic acid sequences that specifically bind to target proteins and other biomolecules (16,30). Aptamers are of interest for imaging, therapy and radiotherapy applications, and they are a unique way to use nucleic acids.
SUMMARY OF THE INVENTION
The present invention is embodied partly in complexes of aptamers with a protein. Complexation of the aptamer with a protein greatly increases the half-life of the aptamer in vivo. The complexes can be non-covalent or covalent. Non-covalent complexes can be formed by covalent attachment of a ligand to the nucleic acid and then complexing the ligand with its specific binding protein.
The aptamer can be one that specifically binds to thrombin. Such aptamers be labeled for detection outside the body and then can be used in methods for imaging blood clots (thrombi) in vivo. In unlabeled form, such aptamers can also be used for inhibiting or preventing coagulation of blood. One problem with such methods is that the half-life of aptamers in serum is typically very short. By complexing the aptamer with a protein (other than the target aptamer binding protein) the half-life of the aptamer in serum is greatly increased. Thus, the present invention provides in vitro methods for imaging thrombi and for inhibiting blood coagulation.
REFERENCES:
patent: 5688670 (1997-11-01), Szostak et al.
patent: 5756291 (1998-05-01), Griffin et al.
patent: WO92/14842 (1992-09-01), None
patent: WO92/14843 (1992-09-01), None
patent: WO95/21853 (1995-08-01), None
patent: 9640159 (1996-12-01), None
patent: WO 02/26932 (2002-04-01), None
Boado, Ruben J. et al, Bioconjugate Chem. 1992, vol. 3, No. 6, pp. 519-523.
Pardridge, William M. et al, Drug Delivery 1, pp. 43-50, 1993.
Tucker, Christopher E. et al, Journal of Chromatography B, 732 (1999) pp. 203-212.
H. Dougan et al., Nuclear Medicine & Biology, vol. 27, 289-297 (2000).
L. C. Bock et al., Nature, vol. 355, 564-566 (Feb. 6, 1992).
H. Dougan et al., Nucleic Acids Research, vol. 25, No. 14, 2897-2901 (1997).
Rosebrough, S.F., “Pharmacokinetics and Biodistribution of Radiolabeled Avidin, Streptavidin and Biotin,” Nucl. Med. and Biol. vol. 20, pp. 663-668, 1993.
Pardridge, W.M. et al., “Drug Delivery of Antisense Oligonucleotides or Peptides to Tissues in Vivo Using an Avidin-Biotin System,” Drug Delivery 1, pp. 43-50, 1993.
Pardridge W.M. et al., “Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein,” FEBS Letters vol. 288, pp. 30-32, 1991.
Kubik, et al. “High-affinity RNA ligands to human &agr;-thrombin” Nucleic Acids Research, 1994, vol. 22, No. 13, pp. 2619-2626.
Latham et al., “The application of a modified nucleotide in aptamer selection: novel thrombin . . . ” Nucleic Acids Research, 1994, vol. 22, No. 14, pp. 2817-2822.
Macaya et al., “Structural and Functional Characterization of Potent Antithrombotic Oligonucleotides . . . ”, Biochemistry, 1995, vol. 34, No. 13, pp. 4478-4492.
Tasset, et al., “Oligonucleotide Inhibitors of Human Thrombin that Bind Distinct Epitopes”, J. Mol. Biol., 1997, vol. 272, pp. 688-698.
Tsiang et al., “Selection of a Suppressor Mutation That Restores Affinity of an Oligonucleotide Inhibitor for Thrombin Using In Vitro Genetics”, Journal of Biological Chemistry, vol. 270, No. 33, Aug. 18, 1995, pp. 19370-19376.
“Renal Clearance of Dextran as a Measure of Glomerular Permeability”, by Gunnar Wallenius,ACTA Societatis Medicorum Upsaliensis, New Series, vol. 59, pp. 1-15 and 84-87.
“Selectivity of Protein Excretion in Patients with the Nephrotic Syndrome”, by Gary R. Joachim, et al.Journal of Clinical Investigation, vol. 43, No. 12, 1964, pp. 2332-2346.
“Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes”, by Wolfgang A. Pieken, et al.,Science, vol. 253, Jul. 19, 1991, pp. 314-317.
“Proteinuria and Aminoaciduria” by Donald E. Oken,Pathophysiology of the Kidney, pp. 739-751.
“Pilot Study of the Efficacy of a Thrombin Inhibitor for Use During Cardiopulmonary Bypass” Abe DeAnda, Jr., et al., Thirteenth Annual Meeting of the Society of Thoracic Surgeons, New Orleans, LA, Jan. 31-Feb. 2, 1994, pp. 344-350.
M. Dennis et al., “Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins”, J. of Biological Chemistry, vol. 277, No. 38, Sep. 2002, pp. 35035-35043.
M. Savage et al., Avidin-Biotin Chemistry: A Handbook, p. 10.
“Biotin Labelling”, Products for DNA Research, Glen Research, p. 20.
B. Chu et al., “Derivatization of unprotected polynucleotides”, Nucleic Acids Research, vol. 11, No. 18, 1983.
E. Jablonski et al., “Preparation of oligodeoxynucleotide-alkaline phosphatase conjugates and their use as hybridization probes”, Nucleic Acids Research, vol. 14, No. 15, 1986.
P. Li et al., “Enzyme-linked synthetic oligonucleotide probes: non-radioactive detection of enterotoxigenicEscherichia coliin faecal specimens”, Nucleic Acids Research, vol. 15, No. 13, 1987.
D. Jellinek et al., “Potent 2′-Amino-2′-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor”, Biochemistry 1995, vol. 34, pp. 11363-11372.
M. Kubik et al., “Isolation and Characterization of 2′-Fluoro-, ′-Amino-, and 2′-Fluoro-/Amino-Modified RNA Ligands to Human IFN-&ggr; That Inhibit Receptor Binding”, Journal of Immunology, 1997, 159: 259-267.
D.J. Hnatowich, “Antisense and Nuclear Medicine”, J. Nuclear Medicine, vol. 40, No. 4, Apr. 1999, pp. 693-703.
F. Dolle et al., “A General Method for Labeling Oligodeoxynucleotides with18F for In Vivo Pet Imaging”, J. of Labelled Compounds and Radiopharmaceuticals, vol. 39, No. 4, pp. 319-330.
N. Watanabe et al., “Labeling of Phosphorothioate Antisense Oligonucleotides with Yttrium-90”, Nuclear Medicine & Biology, vol. 26, pp. 239-243, 1999.
S. Wagner et al., “Synthesis of Copper-64 and Technetium-99M Labeled Oligonucleotides with Macrocyclic Ligands”, Nucleosides & Nucleotides, vol. 16(7-9), pp. 1789-1792, 1997.
TriLink Bio Technologies, Incorporated, “Radioactive Labeling of Oligonucleotides”.
S. Osborne, et al., “Aptamers as therapeutic and diagnostic reagents: problems and prospects”, Current Opinion in Chemical Biology 1997, 1:5-9.
F. Scheller et al., “New Recognition Elements in Biosensing”, Annals of the New York Academy of Sciences, Enzyme Engineering XIV, vol. 864, pp. 37-45, Dec. 1998.
C. Burtis et al. eds., “Tietz Textbook of Clinical Chemistry”, c. 1994 by W.B. Saunders, pp. 688-691, 1698-1712, 2114-2118, 2183, 2205, 2208.
C. Burtis et al. eds., Tietz Fundamentals of Clinical Chemistry 4thEd., c. 1996 by W.B. Saunders, pp. 270, 271, 642, 750, 751.
Dougan Alfred H.
Weitz Jeffrey I.
Birch, Stewart, Solasch & Birch, LLP
McGarry Sean
TRIUMF
LandOfFree
Extending the lifetime of anticoagulant oligodeoxynucleotide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extending the lifetime of anticoagulant oligodeoxynucleotide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extending the lifetime of anticoagulant oligodeoxynucleotide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3330740